Evaluation of predictive and prognostic significance of serum TGF-β1 levels in breast cancer according to HER-2 codon 655 polymorphism

Neoplasma

Volumn 55, Issue 3, 2008, Pages 229-238

  Papadopoulou, E ^a   Anagnostopoulos, K ^a   Tripsianis, G ^a   Tentes, I ^a   Kakolyris, S ^a   Galazios, G ^a   Sivridis, E ^a   Simopoulos, K ^a   Kortsaris, A ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Breast cancer; HER 2; Polymorphism; Serum TGF 1; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ISOLEUCINE; PROGESTERONE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; VALINE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BREAST CANCER; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; CODON; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PREDICTION; PRIMARY TUMOR; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; BREAST TUMOR; EVALUATION; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL RATE;

AGED; BREAST NEOPLASMS; CODON; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 49049100762     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. DATTO MB, LI Y, PANUS JF,et al.. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A. 1995; 92: 5545-5549
2. REISS M, BARCELLOS-HOFF MH.Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat. 1997 Aug; 45: 81-95. Review.
3. STEINER MS, BARRACK ER. Transforming growth factor beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992; 6: 15-25.
4. LIN Y., KIKUCHI S. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer. J. Gastroenterol. Hepatol. 2006; 21(2): 432-437
5. NARAI S, WATANABE M, HASEGAWA H et al. Significance of transforming growth factor β1 as a new tumor marker for colorectal cancer. Int J Cancer 2002; 97: 508-511 (Pubitemid 34027811)
6. SHYR-MING SHEEN-CHEN, HAN-SHIANG CHEN et al. Serum levels of Transforming growth factor-β1 in patients with breast cancer. Arch. Surg. 2001; 136: 937-939.
7. SCHECHTER AL, STERN DF, VAIDYANATHAN L et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312: 513-516 (Pubitemid 15182278)
8. YARDEN Y AND SLIWKOWSKI MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
9. SLAMON DJ, GODOLPHIN W, JONES LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712. (Pubitemid 19147683)
10. ROSS JS, FLETCHER JA, LINETTE GP et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-325.
11. MURAOKA RS, KOH Y, ROEBUCK LR, et al. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol. 2003; 23: 8691-8703
12. PAPEWALLIS J, NIKITIN A AND RAJEWSKY M. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER-2 gene. Nucleic Acids Res. 1991; 19: 5452.
13. TAKANO K, OGASAHARA K et al. Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X-ray structural analysis of the five isoleucine to valine mutants. J. Mol. Biol. 1995; 254: 62-76.
14. XIE D, SHU X, DENG Z et al. Population-based, case-control study of HER-2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000; 92: 412-417. (Pubitemid 30154823)
15. WANG L, HABUCHI T, TAKAHASHI T et al. No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int J Cancer 2002; 97: 787-790. (Pubitemid 34106333)
16. ZUBOR P, VOJVODOVA ADANKO J. et al. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Neoplasma 2006; 3: 49-55. (Pubitemid 43206939)
17. MILLIKAN R, EATON A, WORLEY K et al. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Research and Treatment 2003; 79: 355-364.
18. RUTTER J.L, CHATTERJEE N, WACHOLDER S et al. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology 2003 14: 694-700. (Pubitemid 40417017)
19. KALEMI T, LAMBROPOULOS A, GUEORGUIEV M et al. The association of p53 mutations and p53 codon 72, Her2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece Cancer Letters 2005; 222: 57-65.
20. V655 genotypes in breast cancer cases and controls in the United States. Cancer Letters 2001; 173: 37-41.
21. AMEYAW M, TAYEB M, THORNTON N et al. Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 2002; 47: 172-175.
22. PAPADOPOULOU E, SIMOPOULOS K, TRIPSIANIS G et al. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma, 2007; 54: 367-381
23. BLOOM HJG, RICHARDSON WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-377.
24. th Ed. Berlin: Springer-Verlag, 1992.
25. PAPADOPOULOU E., TRIPSIANIS G. ANAGNOSTOPOULOS K et al. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Neoplasma. Submitted for publication, 2007.
26. SIEGEL PM and MASSAGUÉ J. Cytostatic and apoptotic actions of TGF-β1 in homeostasis and cancer. Cancer 2003; 3: 807-820.
27. TANG B. VU M et al. TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J. Clin. Invest. 2003; 112: 1116-1124.
28. AUVINEN P, LIPPONEN P, JOHANSSON R, et al. Prognostic significance of TGF-β1 and TGF-β2 expressions in female breast cancer. Anticancer Res 1995; 15: 2627-2632
29. IVANOVIC V, TODOROVIC-RACOVIC N et al. Elevated plasma levels of transforming growth factor-β1 in patients with advanced breast cancer: association with disease progression. Eur. J. Cancer 2003, 39: 454-461.
30. MURAWAKI Y, IKUTA Y . Serum markers for fibrosis and plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis. J. Gastroenterol. Hepatol. 1996; 11: 443-450
31. KANG SUP SHIM, KWANG HO KIM, WOON SUP HAN,et al.. Elevated serum levels of transforming growth factor-beta 1 in patients with colorectal carcinoma. Its association with tumor progression and its significan decrease after curative surgical resection. American Cancer Society 1999; 85: 554-561.
32. DOMAGALA-KULAWIK J, HOSER G. Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch. Immunol. Ther. Exp. 2006; 54: 143-147
33. SHARIAT SF, KIM JA, ANDREWS B et al. Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001; 92: 2985-2992. (Pubitemid 33136192)
34. JUNKER U, KNOEFEL B., NUSKE K.et al. . Transforming growth factor-beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine 1996; 8: 794-798
35. SINNREICH O, KRATZSCH A Plasma levels of transforming growth factor-1β and α2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters. The Prostate 2004; 61: 201-208.
36. FRIESS H, YAMANAKA Y et al. Enhanced expression of transforming growth factor-β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993; 105: 1846-1856. (Pubitemid 24002804)
37. COFFEY RJ, SHIPLEY GD, MOSES HL. Production of transforming growth factors by human colon cancer lines. Cancer Res 1986; 46: 1164-1169 (Pubitemid 16048249)
38. KONG F, ANSCHER M, MURASE T et al. Elevated plasma transforming growth factor β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995; 222: 155-162
39. MAEHARA Y, KAKEJI Y, KABASHIMA A et al. Role of transforming growth factor-β1 in invasion and metastasis in gastric cancer. J Clin Oncol 1999; 17: 607-614 (Pubitemid 29075249)
40. DALAL BI, KEOWN PA, GREENBERG AH. Immunohistochemical localization of secreted transforming growth factor-β1 to the advancing edges of primary tumours and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993; 143: 381-389
41. TSUSHIMA H, KAWATA S, TAMURA S et al.: High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996; 110: 375-382.
42. PIEK E, ROBERTS AB. Suppressor and Oncogenic roles of transforming growth factor-β and its signaling pathways in tumorigenesis. Adv Cancer Res 2001; 83: 1-54.
43. WALKER RA AND DEARING SJ. Transforming growth factor-β1 in ductal carcinoma in situ and invasive carcinoma of the breast. Eur. J. Cancer 1992; 28: 641-644.
44. GORSCH SM, MEMOLI VA, STUKEL TA et al. Immunohistochemical staining for transforming growth factor-beta 1 associates with disease progression in human breast cancer. Cancer Res 1992; 52: 6949-6952
45. MURRAY PA, BARRETT-LEE P, TRAVERS M et al. The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 1993: 67: 1408-1412 (Pubitemid 23172888)
46. PETON R, SAXENA B, JONES M et al. Immunohistochemical localization of TGF-β1, TGF-β2 and TGF-β3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J Cell Biol 1991; 115: 1091-1105. (Pubitemid 21909956)
47. SHARIAT SF, SHALEV M, MENESSES-DIAZ A. Preoperative plasma levels of transforming growth factor beta1 (TGF-β1) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001; 19: 2856-2864. (Pubitemid 32538195)
48. UEKI N, NAKAZATO M OHKAWA T.et al. Excessive production of transforming growth factor-β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochem. Biophys. Acta. 1992; 1137: 189-196.
49. MASSAGUE J, CHEIFETZ S, LAIHO M et al. Transforming growth factor-beta. Cancer Surv. 1992; 12: 81-103. Review.
50. SAMUEL SK, HURTA RA KONDAIACH P.et al. Autocrine induction of tumor protease production and invasion by a metallothionen-regulated TGF-β1. EMBO J. 1992; 11: 1599-1605.
51. DERYNCK R, GOEDDEL DV ULRICH A.et al. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res. 1987; 47: 707-712.
52. SETON-ROGERS SE, LU Y, HINES LM et al. Cooperation of the ErbB2 receptor and transforming growth factor β in induction of migration and invasion in mammary epithelial cells. Pnas 2004; 101(5): 1257-1262 (Pubitemid 38182676)
53. WILSON CA, CAJULIS EE, GREEN JL et al. HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res 2005; 7: R1058-R1079.
54. INOUE T, ISHIDA T, TAKENOYAMA M et al. The relationship between the immunodetection of transforming growth factor-beta in lung adenocarcinoma and longer survival rates. Surg Oncol 1995; 4: 51-57
55. ROBSON H, ANDERSON E, JAMES RD, et al. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 1996; 74: 753-758
56. TAKANAMI I, TANAKA F, HASHIZUME T, et al. Transforming growth factor beta isoforms expressions in pulmonary adenocarcinomas as prognostic markers: an immunohistochemical study of one hundred and twenty patients. Oncology 1997; 54: 122-128
57. TSAI JF, JENG JE, CHUANG LY et al. Elevated urinary transforming growth factor-beta 1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer 1997; 76: 244-250